kfk18fyk | Knowledge4COVID-19

Property	Value
?:abstract	Aim: This study aimed to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ), to prevent disease progression, subcutaneously administered to patients with moderate COVID-19 pneumonia and hyperinflammation
is ?:annotates of	<https://research.tib.eu/covid-19/entity/kfk18fyk_hasAnnotation_C0242656>
?:creator	<https://research.tib.eu/covid-19/entity/Potere%2C_N.%3B_Nisio%2C_M._di_Rizzo_G.%3B_Vella%2C_M._la_Polilli_E.%3B_Agostinone%2C_A.%3B_Spacone%2C_A.%3B_Carlo%2C_S._di_Costantini_A.%3B_Abbate%2C_A.%3B_Porreca%2C_E.%3B_Parruti%2C_G.>
?:journal	International_Journal_of_Infectious_Diseases
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/kfk18fyk_HAS_C1609165_PREVENTS_C0242656>
?:source	WHO
?:title	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. (Special Issue: Coronavirus (COVID-19) collection.)
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#959798
?:year	2020

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/kfk18fyk>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/kfk18fyk>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all